My public talk by Davidsfonds Roeselare starts from the question 'why medicines are so expensive?' and answers two questions: What is the cause of these problems? And what can our government and pharmaceutical companies do to provide a solution? Join the talk (in Dutch) on October 6, 2020 in Roeselare: more information.
This month I start a new chapter as Post Doctoral Research Fellow in Global and European Health at the Amsterdam Law School. I look forward to collaborating closely with Prof. Anniek de Ruijter, Prof. Johan Legemaate and other colleagues working at the intersection of law and health.
Colleagues from the Horizon 2020 ELEVATE project and I unpack governments' responsibilities to screen women for precancerous cervical lesions. What's needed? Evidence-driven, rights-based, innovative screening practices that target underserved women globally. Read our article in BMC International Health & Human Rights.
In 12 radio interviews with hosts across Canada I explain the implications for Canadians of the US' recent decision to stockpile experimental treatments for Covid-19. Listen to my interview here (July 6, 2020. Minutes 3-7)
Joined by a group of human rights law scholars, I discuss the right to health implications of accessing current and future essential COVID health care. Listen to my concluding remarks (Minutes 55:20-56:40) Organised by Prof. Lisa Forman at the Dalla Lana School of Public Health's Centre for Global Health.
Prof. Sigrid Sterckx and I published our opinion piece titled 'new rules in the race for a vaccine' (in Dutch) in the Belgian newspaper, De Standaard. The conditions we set now about funding the development of vaccines and drugs and rights to the end products will determine who has access to those products in the future.
This month I'm presenting my legal analysis of how medicines access is embedded in legislation for universal health coverage at the 2020 Conferences of the International Society to Improve the Use of Medicines.
Our Global Minds project on political priority for adolescent contraception in Uganda wraps up with a policy workshop on December 6, 2019 in the Ugandan Ministry of Health to discuss the results.
For the next six weeks I'll be working closely with Prof. Anita Wagner in the Division of Health Policy and Insurance Research to explore legal approaches for access to medicines in Brazil and China.
Health researchers and advocates Dr. Ellen 't Hoen (Medicines Law & Policy), Ms. Salomé Meyer (Cancer Alliance South Africa), Mr. Patrick Durisch (Public Eye), Mr. Wilbert Bannenberg (Pharmaceutical Accountability Foundation), Dr. Tim Reed (Health Action International), Ms. Melissa Barber (Harvard University), and I published a call in Lancet Oncology for governments & stakeholders to act now to decrease the price of new essential cancer medicines. Continue in the Lancet Oncology...
In July 2019, the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines published the 21st Model List of Essential Medicines. The Committee adopted some of the arguments that myself, Dr. Lucía Berro Pizzarossa and Prof. Jelle Stekelenberg put forward in our 2018 debate article to move mifepristone & misoprostol for medical abortion from the ‘complementary’ to the ‘core’ list of essential medicines. However, the Committee did not remove the statement "(for use) where permitted under national law and where culturally acceptable" from the misoprostol-mifepristone entry.
Our study finds that WHO’s 2001 guidelines to develop and implement a national medicines policy have guided the content and language of many subsequent national medicines policies. WHO and national policy makers can use the principles and the practical examples identified in this study to further align national medicines policies with human rights law and with Target 3.8 for universal access to essential medicines in the Sustainable Development Goals. Continue reading in PLoS One...
Read more about my project on national laws & policies for access to medicines...
"Saving mothers and children, and fighting disease are two of Rotary's six areas of focus," explained Dr. Perehudoff, "But what good are the health centres Rotary clubs build, and the doctors and nurses they train if they can't afford to have medicines on shelves and in patients' hands?" Rotary District 7280 Governor Mr. Scott Bayline invited me to address his District Conference, this year in Erie, Pennsylvania from May 17-19, 2019. I spoke of the challenge of high medicines prices and their potential impact on the future success of Rotary's health projects. Continue reading in the ICRH Newsletter...
In our last blog post, Prof. Jennifer Sellin and I asked whether the 2nd WHO Fair Pricing Forum would achieve a shared commitment and promote (regulatory) actions that dissuade the pharmaceutical industry from seeking excessively high medicine prices. Did the second WHO Fair Pricing Forum make good on its promise? And how can the next global health policy meeting—the upcoming 72nd World Health Assembly—advance the Forum’s work? Continue reading...
Photo: Public protests outside the WHO Fair Pricing Forum, Public Eye & MSF Access Campaign (credit Public Eye).
Expensive medicines are a ubiquitous challenge from which no government is immune. The pharmaceutical industry’s human rights responsibilities are globally endorsed yet rarely enforced. Prof. Jennifer Sellin and I look to the forthcoming 2nd WHO Fair Pricing Forum for leadership and a shared commitment to use all legal options to hold the industry to account for its human rights responsibilities. Continue reading...